Clearpoint Neuro (CLPT) Q3 2024 earnings summary

Executive summary

• Achieved record Q3 2024 revenue of $8.1 million, up 41% year-over-year, driven by new product launches, expanded customer base, and growth across all four business pillars.

• Platform technology with over 10 years of commercial experience in precision MRI-guided and OR-based therapies, expanding via A.I., machine learning, and strategic partnerships.

• Customer base includes 90+ neurosurgery and research centers, targeting 100+ by 2025, with over 7,000 procedures performed using the platform.

• Completed $16.2 million public stock offering in March 2024 and fully repaid $10 million convertible note in August 2024, resulting in a debt-free balance sheet.

• Total addressable market exceeds $12 billion across products, pipeline, and partnerships.

Financial highlights

• Q3 2024 revenue was $8.1 million, up 41% year-over-year; nine-month revenue was $23.6 million, up 38%.

• Gross margin improved to 60% in Q3 2024 (from 57% in Q3 2023) and 61% for the nine months (from 56%).

• Q3 2024 net loss was $5.0 million ($0.18/share); nine-month net loss was $13.5 million ($0.50/share).

• Operational cash burn reduced by 33% year-over-year to $1.2 million in Q3; cash used in operations was $7.7 million for the nine months.

• Cash and cash equivalents stood at $21.6 million as of September 30, 2024, with no outstanding debt.

Outlook and guidance

• Full-year 2024 revenue expected between $30 million and $33 million, representing 25%-38% growth and a 23.8% CAGR as of Q3 2024.

• Cash flow break-even targeted by end of 2025, supported by strong cash position and no debt.

• Expects continued growth from new product launches, global customer activations, and expansion in neurosurgery and cell/gene therapy markets.

• Plans to expand global footprint to 100+ centers and integrate new software and therapy solutions.